Advanced Squamous Non-Small Cell Lung Cancer Progressing after First-Line Chemotherapy
Conditions
Interventions
Test group:Intravenous Docetaxel Chemotherapy Combined with Bronchial Artery Embolization
Sponsors
Lishui Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily participate and sign informed consent. 2. Aged >=18 years, regardless of gender. 3. ECOG Performance Status score: 0-2; 4. Histologically or cytologically confirmed locally advanced and/or metastatic lung squamous cell carcinoma (LSCC); Diagnosed as stage IIIB, IIIC, or IV according to the 2023 UICC Lung Cancer Staging System (9th edition). 5. Target lesions meeting Recist 1.1 criteria: Diameter >=20 mm for non-nodal lesions, OR Short-axis diameter >=15 mm for lymph nodes. 6. Contrast-enhanced CT angiography (CTA) demonstrating tumor-feeding bronchial arteries or other systemic arteries. 7. Organ Function Requirements (within 7 days pre-treatment): a) Hematological Parameters (no transfusion within 14 days): Hemoglobin (Hb) >=9 g/dL Absolute Neutrophil Count (ANC) >=1.5×10?/L Platelets (PLT) >=90×10?/L; b) Biochemical Parameters: Total Bilirubin (TBIL) =60 mL/min; c) Cardiac Function: Left Ventricular Ejection Fraction (LVEF) >=50% (lower limit of normal) by Doppler ultrasound. 8. Women of childbearing potential: Must use contraception (e.g., IUD, oral contraceptives, condoms) during and for 6 months post-study; Negative serum/urine pregnancy test within 7 days before enrollment; Non-lactating. Male patients: Must use contraception during and for 6 months post-study.
Exclusion criteria
Exclusion criteria: 1.Patients with lung adenocarcinoma or small cell lung carcinoma (including combined small cell and non-small cell lung carcinoma); 2.Previous bronchial artery chemoembolization (BACE) or bronchial artery embolization (BAE) therapy; Prior docetaxel-based chemotherapy. 3.Other active malignancies requiring simultaneous treatment. 4.Treatment-related adverse reactions (excluding alopecia) from prior systemic anticancer therapy not recovered to Grade =1 per NCI-CTCAE v5.0; 5.Contraindications to BAE or chemotherapy. 6.Current participation in other clinical studies or =2×10³ copies/mL; HCV: HCV RNA-positive AND abnormal liver function; HBV/HCV co-infection; Active tuberculosis. 8.Any condition that may lead to premature study termination per investigator's judgment, including: Severe comorbid diseases; Clinically significant laboratory abnormalities; Social/familial factors compromising subject safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate?Duration of Overall Response;Tumor markers;Progression Free Survival;Overall Survival;ECOG Performance Status score; | — |
Countries
China
Contacts
Public ContactJiansong Ji
Lishui Central Hospital
Outcome results
None listed